NCT02239354: A trial that was reported late by ViaCyte
This trial has reported, although it was 396 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02239354 |
|---|---|
| Title | A Prospective, Multicenter, Open-Label, First-in-Human Phase 1/2 Study With Two Cohorts to Evaluate the Safety, Tolerability, and Efficacy of Various Doses of VC-01™ Combination Product in Subjects With Type 1 Diabetes Mellitus |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Sept. 30, 2014 |
| Completion date | Dec. 31, 2017 |
| Required reporting date | Dec. 31, 2020, midnight |
| Actual reporting date | Jan. 31, 2022 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 396 |